CareRx (CRRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $92.0 million, down from $94.5 million in Q2 2023 but up from $89.7 million in Q1 2024, mainly due to changes in average beds serviced and the closure of a non-core Vancouver pharmacy.

• Adjusted EBITDA improved to $7.5 million, up from $7.0 million in Q2 2023 and $7.4 million in Q1 2024, driven by operational efficiencies, cost savings, and improved supply terms from a renegotiated procurement agreement.

• Net loss for Q2 2024 was $1.4 million, compared to net income of $1.9 million in Q2 2023, mainly due to non-cash adjustments and a one-time intangible asset impairment from the sale of a non-core asset.

• Leadership changes included a new Chairman, interim CFO, and SVP of IT, strengthening the executive team and supporting technology and AI initiatives.

• Sale of a non-core pharmacy operation closed for $0.4 million, impacting results through a one-time impairment and optimizing resource allocation.

Financial highlights

• Revenue for Q2 2024 was $91.97 million, down from $94.49 million in Q2 2023 but up from $89.7 million sequentially; six months 2024 revenue was $181.70 million.

• Adjusted EBITDA margin increased to 8.2% in Q2 2024, up 70 basis points year-over-year and flat sequentially.

• Net loss per share (basic and diluted) for Q2 2024 was ($0.02), compared to $0.03 in Q2 2023.

• Cash balance at quarter-end was $7.2 million, down from $11.4 million in Q1 2024, due to loan repayments.

• Cash provided by operations in Q2 2024 was $8.1 million, up from $5.3 million in Q2 2023.

Outlook and guidance

• Management expects continued margin and adjusted EBITDA growth, supported by a robust pipeline, operational improvements, and a focus on procurement, standardization, and Lean methodology.

• More than half of targeted bed growth for the second half of 2024 has been secured, pending regulatory license transfers.

• Margins are expected to remain relatively stable, with some seasonal labor cost variability.

• Full benefit of the amended supply agreement expected in Q3 2024.

• Growth strategy includes organic bed wins, expansion into new care settings, and continued M&A in a fragmented market.